Bupropion/zonisamide

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Bupropion/zonisamide
Bupropion and zonisamide.svg
Combination of
Bupropion Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Zonisamide Sulfonamide anticonvulsant
Clinical data
Legal status
  • Investigational
  (verify)

Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.[1] It is being developed by Orexigen Therapeutics. It is currently at phase II testing.[2][3] The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments.[4] When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.

Empatic was called Excalia before its name was changed.[5]

See also

References

  1. ↑ Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Orexigen says trial of 2nd obesity drug meets goal
  5. ↑ Empatic Obesity Drug Information and News



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Bupropion/zonisamide&oldid=3575847"